BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu S, Ling S, Shan Q, Ye Q, Zhan Q, Jiang G, Zhuo J, Pan B, Wen X, Feng T, Lu H, Wei X, Xie H, Zheng S, Xiang J, Shen Y, Xu X. Self-Activated Cascade-Responsive Sorafenib and USP22 shRNA Co-Delivery System for Synergetic Hepatocellular Carcinoma Therapy. Adv Sci (Weinh) 2021;8:2003042. [PMID: 33717848 DOI: 10.1002/advs.202003042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, Dong X, Zhang Y. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio 2022;16:100358. [PMID: 35880099 DOI: 10.1016/j.mtbio.2022.100358] [Reference Citation Analysis]
2 Zhao J, Guo J, Wang Y, Ma Q, Shi Y, Cheng F, Lu Q, Fu W, Ouyang G, Zhang J, Xu Q, Hu X. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Front Oncol 2022;12:920287. [DOI: 10.3389/fonc.2022.920287] [Reference Citation Analysis]
3 Xiang J, Liu J, Liu X, Zhou Q, Zhao Z, Piao Y, Shao S, Zhou Z, Tang J, Shen Y. Enzymatic drug release cascade from polymeric prodrug nanoassemblies enables targeted chemotherapy. J Control Release 2022;348:444-55. [PMID: 35691498 DOI: 10.1016/j.jconrel.2022.06.007] [Reference Citation Analysis]
4 Yao M, Wang X, Huang K, Jia X, Xue J, Guo B, Chen J. Fluorescence-Reporting-Guided Tumor Acidic Environment-Activated Triple Photodynamic, Chemodynamic, and Chemotherapeutic Reactions for Efficient Hepatocellular Carcinoma Cell Ablation. Langmuir 2022. [PMID: 35467866 DOI: 10.1021/acs.langmuir.1c03211] [Reference Citation Analysis]
5 Chen D, Liu J, Zang L, Xiao T, Zhang X, Li Z, Zhu H, Gao W, Yu X. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients. Int J Biol Sci 2022;18:360-73. [PMID: 34975338 DOI: 10.7150/ijbs.66913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li T, Shi W, Yao J, Hu J, Sun Q, Meng J, Wan J, Song H, Wang H. Combinatorial nanococktails via self-assembling lipid prodrugs for synergistically overcoming drug resistance and effective cancer therapy. Biomater Res 2022;26. [DOI: 10.1186/s40824-022-00249-7] [Reference Citation Analysis]
7 Pan B, Wei X, Xu X. Patient-derived xenograft models in hepatopancreatobiliary cancer. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02454-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tang X, Liu B, Zhang C, Tang W, Liang S, Xiao Y, Deng R, Li Z. SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. Front Oncol 2021;11:773045. [PMID: 34950583 DOI: 10.3389/fonc.2021.773045] [Reference Citation Analysis]
9 Zheng S, Wang J, Ding N, Chen W, Chen H, Xue M, Chen F, Ni J, Wang Z, Lin Z, Jiang H, Liu X, Wang L. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. J Nanobiotechnology 2021;19:381. [PMID: 34802453 DOI: 10.1186/s12951-021-01127-5] [Reference Citation Analysis]
10 Wei J, Xia Y, Meng F, Ni D, Qiu X, Zhong Z. Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma. Biomacromolecules 2021;22:4814-22. [PMID: 34677048 DOI: 10.1021/acs.biomac.1c01103] [Reference Citation Analysis]
11 Feng T, Ling S, Xu C, Ying L, Su D, Xu X. Ubiquitin-specific peptidase 22 in cancer. Cancer Lett 2021;514:30-7. [PMID: 33989708 DOI: 10.1016/j.canlet.2021.05.004] [Reference Citation Analysis]